- Biomarker developer Oxford BioDynamics welcomed news that Mitsubishi Tanabe Pharma America had enrolled the first patient in a new clinical study.

Mitsubishi Tanabe, its partners, and trial investigators would use Oxford BioDynamicss proprietary EpiSwitch technology platform to assess the rate of disease progression using eepigenetic biomarkers.

The study had been designed to identify and measure specific biomarkers and clinical assessments in up to 300 people with amyotrophic lateral sclerosis in the US who had begun treatment on Radicava.

Story provided by